Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Plus: A stomach flu vaccine, the health impacts of California’s wildfires, lots of nine-figure deals for healthcare startups ...

TD Cowen analyst Steve Scala reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $900.00.Stay ...

Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's ...

LAS VEGAS, NV, UNITED STATES, January 15, 2025 /EINPresswire / -- The Alopecia Areata market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 465.16% and ...

Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...

Jefferies analyst Akash Tewari maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report) today and set a price target of ...

JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in ...

Eli Lilly expects to miss its recent revenue estimate for 2024 by about $400 million, according to a preliminary report.

Current treatments for dermatomyositis include various immunosuppressants and immunosuppressive agents, including ...